NASDAQ: TRDA
Entrada Therapeutics Inc Stock

$8.94+0.07 (+0.79%)
Updated Apr 29, 2025
TRDA Price
$8.94
Fair Value Price
N/A
Market Cap
$336.10M
52 Week Low
$7.10
52 Week High
$21.79
P/E
5.08x
P/B
0.78x
P/S
3.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$210.78M
Earnings
$65.63M
Gross Margin
100%
Operating Margin
31.54%
Profit Margin
31.1%
Debt to Equity
0.23
Operating Cash Flow
-$42M
Beta
1.04
Next Earnings
Jun 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

TRDA Overview

Entrada Therapeutics Incorporated is a biotechnology company developing Endosomal Escape Vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform is the base for a portfolio of oligonucleotide, antibody, and enzyme-based programs.The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne Muscular Dystrophy and Myotonic Dystrophy-Type 1. The company was known as CycloPorters Inc. until 2017. It was incorporated in 2016 and is headquartered in Boston, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TRDA's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TRDA
Ranked
#130 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TRDA news, forecast changes, insider trades & much more!

TRDA News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRDA is good value based on its earnings relative to its share price (5.08x), compared to the US market average (29.19x)
P/E vs Market Valuation
TRDA is good value based on its earnings relative to its share price (5.08x), compared to the US Biotechnology industry average (-158.75x)
P/E vs Industry Valuation
TRDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more TRDA due diligence checks available for Premium users.

Valuation

TRDA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
5.08x
Industry
-158.75x
Market
29.19x
TRDA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TRDA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

TRDA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.78x
Industry
4.37x
TRDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TRDA's financial health

Profit margin

Revenue
$37.4M
Net Income
$1.1M
Profit Margin
3%
TRDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TRDA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$526.3M
Liabilities
$97.6M
Debt to equity
0.23
TRDA's short-term assets ($440.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRDA's short-term assets ($440.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.6M
Investing
$53.4M
Financing
$1.4M
TRDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRDA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TRDAC$336.10M+0.79%5.08x0.78x
ALLOD$334.59M-1.91%-1.17x0.79x
TPSTF$333.85M-6.26%-4.89x17.46x
MBXD$329.90M+5.56%-1.70x1.28x
CKPT$343.43M-0.24%-2.89x-27.20x

Entrada Therapeutics Stock FAQ

What is Entrada Therapeutics's quote symbol?

(NASDAQ: TRDA) Entrada Therapeutics trades on the NASDAQ under the ticker symbol TRDA. Entrada Therapeutics stock quotes can also be displayed as NASDAQ: TRDA.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

What is the 52 week high and low for Entrada Therapeutics (NASDAQ: TRDA)?

(NASDAQ: TRDA) Entrada Therapeutics's 52-week high was $21.79, and its 52-week low was $7.10. It is currently -58.97% from its 52-week high and 25.92% from its 52-week low.

How much is Entrada Therapeutics stock worth today?

(NASDAQ: TRDA) Entrada Therapeutics currently has 37,594,630 outstanding shares. With Entrada Therapeutics stock trading at $8.94 per share, the total value of Entrada Therapeutics stock (market capitalization) is $336.10M.

Entrada Therapeutics stock was originally listed at a price of $23.95 in Oct 29, 2021. If you had invested in Entrada Therapeutics stock at $23.95, your return over the last 3 years would have been -62.67%, for an annualized return of -28% (not including any dividends or dividend reinvestments).

How much is Entrada Therapeutics's stock price per share?

(NASDAQ: TRDA) Entrada Therapeutics stock price per share is $8.94 today (as of Apr 29, 2025).

What is Entrada Therapeutics's Market Cap?

(NASDAQ: TRDA) Entrada Therapeutics's market cap is $336.10M, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Entrada Therapeutics's market cap is calculated by multiplying TRDA's current stock price of $8.94 by TRDA's total outstanding shares of 37,594,630.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.